Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-gamma ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.
Liniger
Matthias
M
Berna Biotech (a Crucell Company), Rehhagstrasse 79, CH-3018 Bern, Switzerland.
Zuniga
Armando
A
Tamin
Azaibi
A
Azzouz-Morin
Teldja N
TN
Knuchel
Marlyse
M
Marty
Rene R
RR
Wiegand
Marian
M
Weibel
Sara
S
Kelvin
David
D
Rota
Paul A
PA
Naim
Hussein Y
HY
D000818:Animals; D030801:Animals, Genetically Modified; D005822:Genetic Vectors / Q000737:chemistry; D008458:Measles Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D008459:Measles virus / Q000378:metabolism / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009500:Neutralization Tests; D019590:Nucleocapsid Proteins / Q000235:genetics; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control*; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics / Q000276:immunology
D008458:Measles Vaccine; D008562:Membrane Glycoproteins; D019590:Nucleocapsid Proteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV